These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20729158)

  • 61. The added value of screening mammography in improved screening for other cancers.
    Carlos RC
    J Am Coll Radiol; 2004 Aug; 1(8):597-600. PubMed ID: 17411659
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Re: Why are results of organised mammography screening so difficult to interpret?].
    Zahl PH
    Tidsskr Nor Laegeforen; 2014 Sep; 134(16):1544-5. PubMed ID: 25178207
    [No Abstract]   [Full Text] [Related]  

  • 63. Evaluating health care performance: strengths and limitations of multilevel analysis.
    Tan A; Freeman JL; Freeman DH
    Biom J; 2007 Aug; 49(5):707-18. PubMed ID: 17638296
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ["Bending and breaking"--an experimental model for breast screening becomes a play-thing of interests. Defamation campaign against physicians performing mammography].
    Altland H
    Radiologe; 1999 Oct; 39(10):M159-61. PubMed ID: 10550395
    [No Abstract]   [Full Text] [Related]  

  • 65. Expanding Cancer Registries to Capture Method of Detection.
    Eby PR; Destounis S;
    J Am Coll Radiol; 2024 Mar; 21(3):411-414. PubMed ID: 37952149
    [No Abstract]   [Full Text] [Related]  

  • 66. Comparison of two test-objects for daily quality control of the technical aspects of mammography screening units.
    De Luyck I; Mol H; Van Loon R
    J Belge Radiol; 1996 Apr; 79(2):90. PubMed ID: 8767841
    [No Abstract]   [Full Text] [Related]  

  • 67. A graphic method of estimating the specificity of screening programmes from incomplete follow-up data.
    Brecht JG; Robra BP
    Methods Inf Med; 1987 Jan; 26(1):53-8. PubMed ID: 3561259
    [No Abstract]   [Full Text] [Related]  

  • 68. [Quality Variation in Switzerland: Analysis of Mammary Resections for Breast Cancer using the Quality Indicator of Breast Preservation].
    Moser D; von Ahlen C; Geissler A
    Gesundheitswesen; 2022 Jun; 84(6):539-546. PubMed ID: 34847592
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mammography Performance Benchmarks in an Era of Value-based Care.
    Lee JM; Miglioretti DL; Burnside ES; Morris EA; Smith RA; Lehman CD
    Radiology; 2017 Aug; 284(2):605-607. PubMed ID: 28723290
    [No Abstract]   [Full Text] [Related]  

  • 70. Quality determinants of mammography: guideline overview. Agency for Health Care Policy and research.
    J Natl Med Assoc; 1995 Feb; 87(2):91-2. PubMed ID: 7897689
    [No Abstract]   [Full Text] [Related]  

  • 71. [A screening for all. How to make screening programmes more inclusive].
    Ferrante G; Di Stefano F; Piccinelli C; Giordano L
    Epidemiol Prev; 2023; 47(6):328-330. PubMed ID: 38314542
    [No Abstract]   [Full Text] [Related]  

  • 72. Assessment of changes to screening programmes: why randomisation is important.
    Bell KJ; Bossuyt P; Glasziou P; Irwig L
    BMJ; 2015 Mar; 350():h1566. PubMed ID: 25825377
    [No Abstract]   [Full Text] [Related]  

  • 73. Use and Misuse of Quality Indicators to Characterize Screening as Excessive.
    O'Hanlon CE
    JAMA Intern Med; 2021 Nov; 181(11):1542-1543. PubMed ID: 34542580
    [No Abstract]   [Full Text] [Related]  

  • 74. Use and Misuse of Quality Indicators to Characterize Screening as Excessive-Reply.
    Simon J; Panzer J; Sinsky CA
    JAMA Intern Med; 2021 Nov; 181(11):1543-1544. PubMed ID: 34542572
    [No Abstract]   [Full Text] [Related]  

  • 75. Humanized Health Care: Human-Centered Design in Screening Mammography.
    Chadalavada SC; Roebker JA; Brown A; Tobler JJ; Wahab SA; Kapur S; Wahab RA; Mahoney M; Vagal A
    J Am Coll Radiol; 2024 Jul; 21(7):1145-1148. PubMed ID: 38185443
    [No Abstract]   [Full Text] [Related]  

  • 76. Measuring longitudinal adherence to screening needs international standards.
    Brändle K; Bulliard JL
    Breast; 2023 Feb; 67():129. PubMed ID: 36210239
    [No Abstract]   [Full Text] [Related]  

  • 77. Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects.
    Herrmann C; Morant R; Walser E; Mousavi M; Thürlimann B
    BMC Cancer; 2021 Mar; 21(1):229. PubMed ID: 33676446
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines.
    Ulyte A; Wei W; Dressel H; Gruebner O; von Wyl V; Bähler C; Blozik E; Brüngger B; Schwenkglenks M
    PLoS One; 2020; 15(4):e0231409. PubMed ID: 32298325
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Breast cancer screening attendance in two Swiss regions dominated by opportunistic or organized screening.
    Eichholzer M; Richard A; Rohrmann S; Schmid SM; Leo C; Huang DJ; Güth U
    BMC Health Serv Res; 2016 Sep; 16(1):519. PubMed ID: 27663642
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Variation in performance in low-volume mammography screening programmes: experience from Switzerland.
    Bulliard JL; Ducros C; Dayer E; Arzel B; Levi F
    Cancer Epidemiol; 2011 Jun; 35(3):293-7. PubMed ID: 20729158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.